Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 8.31
RGLS's Cash to Debt is ranked higher than
75% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. RGLS: 8.31 )
RGLS' s 10-Year Cash to Debt Range
Min: 1.76   Max: No Debt
Current: 8.31

Equity to Asset 0.72
RGLS's Equity to Asset is ranked higher than
79% of the 728 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.60 vs. RGLS: 0.72 )
RGLS' s 10-Year Equity to Asset Range
Min: -1.26   Max: 0.76
Current: 0.72

-1.26
0.76
F-Score: 3
Z-Score: 4.61
M-Score: -3.27
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -90.97
RGLS's Operating margin (%) is ranked lower than
52% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.25 vs. RGLS: -90.97 )
RGLS' s 10-Year Operating margin (%) Range
Min: -180.19   Max: -51.76
Current: -90.97

-180.19
-51.76
Net-margin (%) -95.40
RGLS's Net-margin (%) is ranked lower than
52% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.16 vs. RGLS: -95.40 )
RGLS' s 10-Year Net-margin (%) Range
Min: -180.9   Max: -55.13
Current: -95.4

-180.9
-55.13
ROE (%) -19.97
RGLS's ROE (%) is ranked higher than
51% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.97 vs. RGLS: -19.97 )
RGLS' s 10-Year ROE (%) Range
Min: -28.04   Max: -19.97
Current: -19.97

-28.04
-19.97
ROA (%) -15.17
RGLS's ROA (%) is ranked higher than
51% of the 777 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.87 vs. RGLS: -15.17 )
RGLS' s 10-Year ROA (%) Range
Min: -17.73   Max: -15.17
Current: -15.17

-17.73
-15.17
ROC (Joel Greenblatt) (%) -472.45
RGLS's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.60 vs. RGLS: -472.45 )
RGLS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -472.45   Max: -229.49
Current: -472.45

-472.45
-229.49
» RGLS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with RGLS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.61
RGLS's P/B is ranked higher than
60% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. RGLS: 3.61 )
RGLS' s 10-Year P/B Range
Min: 2.5   Max: 8.83
Current: 3.61

2.5
8.83
P/S 20.09
RGLS's P/S is ranked lower than
64% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.70 vs. RGLS: 20.09 )
RGLS' s 10-Year P/S Range
Min: 0.11   Max: 23.91
Current: 20.09

0.11
23.91
EV-to-EBIT -6.64
RGLS's EV-to-EBIT is ranked higher than
59% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.72 vs. RGLS: -6.64 )
RGLS' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -6.64

Current Ratio 9.58
RGLS's Current Ratio is ranked higher than
93% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.47 vs. RGLS: 9.58 )
RGLS' s 10-Year Current Ratio Range
Min: 1.64   Max: 12.36
Current: 9.58

1.64
12.36
Quick Ratio 9.58
RGLS's Quick Ratio is ranked higher than
94% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. RGLS: 9.58 )
RGLS' s 10-Year Quick Ratio Range
Min: 1.64   Max: 12.36
Current: 9.58

1.64
12.36

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.14
RGLS's Price/Net Cash is ranked higher than
97% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. RGLS: 4.14 )
RGLS' s 10-Year Price/Net Cash Range
Min: 3.66   Max: 8.92
Current: 4.14

3.66
8.92
Price/Net Current Asset Value 4.14
RGLS's Price/Net Current Asset Value is ranked higher than
96% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. RGLS: 4.14 )
RGLS' s 10-Year Price/Net Current Asset Value Range
Min: 3.66   Max: 8.53
Current: 4.14

3.66
8.53
Price/Tangible Book 3.65
RGLS's Price/Tangible Book is ranked higher than
74% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.53 vs. RGLS: 3.65 )
RGLS' s 10-Year Price/Tangible Book Range
Min: 3.34   Max: 7.38
Current: 3.65

3.34
7.38
Price/Median PS Value 1.47
RGLS's Price/Median PS Value is ranked higher than
62% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.26 vs. RGLS: 1.47 )
RGLS' s 10-Year Price/Median PS Value Range
Min: 0.01   Max: 1.69
Current: 1.47

0.01
1.69

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:7RG.Germany
Regulus Therapeutics Inc. was incorporated in the State of Delaware. It is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a broad range of diseases. The Company was formed in 2007 when Alnylam Pharmaceuticals, Inc., or Alnylam, and Isis Pharmaceuticals, Inc., or Isis, contributed significant intellectual property, know-how and financial and human capital to pursue the development of drugs targeting microRNAs pursuant to a license and collaboration agreement. microRNAs are recently discovered, naturally occurring ribonucleic acid, or RNA, molecules that play a critical role in regulating key biological pathways. Scientific research has shown the improper balance, or dysregulation, of microRNAs is directly linked to many diseases. The Company benefits substantially from the collective therapeutic RNA expertise of its founding companies, including established proprietary oligonucleotide-based technologies, and broad and dominant intellectual property estates specific to chemically modified oligonucleotides. The Company has exclusive rights to over 900 patents and patent applications pertaining to oligonucleotide modifications, conjugates, and design patterns, all for use in targeting microRNA for therapeutic applications. The microRNA therapeutics are oligonucleotide medicines that modulate the function of microRNAs, correcting the imbalance of gene expression and associated cellular pathways to treat human disease. It is currently optimizing anti-miRs targeting miR-21, miR-122, miR-33 and miR-10b for development candidate selection. It has established strategic alliances with AstraZeneca, GSK and Sanofi and it will continue to seek partners who can bring therapeutic expertise, development and commercialization capabilities and funding to allow it to maximize the potential of its microRNA product platform. Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those it is developing.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK